Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsTransplantation, AutologousStem Cell TransplantationHematopoietic Stem Cell MobilizationTransplantation ChimeraGranulocyte Colony-Stimulating FactorGraft SurvivalBusulfanBone Marrow TransplantationTissue DonorsAntigens, CD34Treatment OutcomeVidarabineGraft vs Tumor EffectLeukapheresisRecurrenceMyeloablative AgonistsGraft vs Leukemia EffectImmunosuppressive AgentsStem CellsMelphalanCombined Modality TherapyHistocompatibility TestingMultiple MyelomaHematopoietic Stem CellsRemission InductionRetrospective StudiesHistocompatibilityCyclophosphamideSurvival AnalysisCord Blood Stem Cell TransplantationLeukemiaWhole-Body IrradiationBlood Component RemovalAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalLeukemia, Myeloid, AcuteSalvage TherapyLymphoma, Non-HodgkinSurvival RatePrecursor Cell Lymphoblastic Leukemia-LymphomaEtoposideCytomegalovirus InfectionsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTime FactorsLymphocyte TransfusionChronic DiseaseMyelodysplastic SyndromesAntineoplastic Agents, AlkylatingHLA AntigensLiver TransplantationTransplantation, IsogeneicLymphocyte DepletionInfectionT-LymphocytesThiotepaCytarabineAnemia, AplasticHodgkin DiseaseSiblingsPOEMS SyndromeFollow-Up StudiesHematopoiesisNeoplasm, ResidualTransplantation ImmunologyVincristineCyclosporineHematologic DiseasesMesenchymal Stem Cell TransplantationAntilymphocyte SerumImmunosuppressionAmyloidosisCarmustineFatal OutcomeLymphomaKidney TransplantationCell TransplantationBlood CellsPrognosisAcute DiseaseOpportunistic InfectionsIfosfamideChimerismEmbryonic Stem CellsNeoplasmsAntineoplastic AgentsMinor Histocompatibility AntigensHepatic Veno-Occlusive DiseaseBone MarrowProspective StudiesPlatelet CountImmunophenotypingVirus ActivationFeasibility StudiesBlood Donors